Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 26:9:903123.
doi: 10.3389/fsurg.2022.903123. eCollection 2022.

Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma

Wei-Yu Lin  1   2   3   4 , Meng-Hung Lin  5 , Yao-Hsu Yang  5   6   7 , Wen-Cheng Chen  2   8 , Cih-En Huang  9 , Miao-Fen Chen  2   8 , Chun-Te Wu  2   10
Affiliations

Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma

Wei-Yu Lin et al. Front Surg. .

Abstract

Background: Whether nephroureterectomy (NU) provides survival benefits in patients with stage IV upper tract urothelial carcinoma (UTUC) remains unclear. We compared the effect of chemotherapy (CT) alone with that of CT combined with NU (CT + NU) on the overall survival (OS) of patients with stage IV nonmetastatic UTUC (nmUTUC) and metastatic UTUC (mUTUC).

Patients and methods: This multicenter retrospective cohort study included the data of patients with UTUC undergoing CT alone or CT + NU from the Chang Gung Cancer Database (2002-2015) and followed them until August 2017. OS and hazard ratios (HRs) were assessed using the Kaplan-Meier method and Cox proportional hazards model, respectively.

Results: This study included 308 patients with stage IV UTUC, comprising 139 with nmUTUC and 169 with mUTUC. Moreover, 91 (74.6%) patients with nmUTUC and 31 (25.4%) patients with mUTUC received NU. The CT + NU group had a higher 3-year OS rate (41.0.% vs 16.7%, p < 0.001), longer median OS duration (20.7 vs 9.0 months, p < 0.001), and lower risk of death (HR, 0.48; 95% confidence interval, 0.36-0.66; p < 0.001) than did the CT-alone group. Similarly, patients with mUTUC who underwent CT + NU had a longer median OS duration (25.0 vs 7.8 months, p < 0.001) and lower risk of death (HR, 0.37; 95% confidence interval, 0.23-0.59; p < 0.001) than did those who received CT alone.

Conclusion: Compared with CT alone, NU + CT can provide survival benefits to patients with nonmetastatic and metastatic stage IV UTUC.

Keywords: metastasis; nephroureterectomy; nonmetastasis; stage IV; upper tract urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier 3-year overall survival curves for patients with stage IV upper urinary tract urothelial cancer stratified by (A) treatment type and (B) cM Stage.
Figure 2
Figure 2
Kaplan–Meier 3-year overall survival curves for patients with stage IV upper urinary tract urothelial cancer stratified by treatment type in (A) nonmetastatic and (B) metastatic.
See this image and copyright information in PMC

References

    1. Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. (2011) 107:1059–64. 10.1111/j.1464-410X.2010.09675.x - DOI - PubMed
    1. Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Roupret M, et al. Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma. Eur Urol. (2017) 71:714–18. 10.1016/j.eururo.2016.11.012 - DOI - PubMed
    1. Leow JJ, Chong KT, Chang SL, Bellmunt J. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open. (2016) 1:e000126. 10.1136/esmoopen-2016-000126 - DOI - PMC - PubMed
    1. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. (2009) 115:1224–33. 10.1002/cncr.24135 - DOI - PubMed
    1. Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. (2010) 76:895–901. 10.1016/j.urology.2010.04.020 - DOI - PubMed